Form C-U BIOCURITY PHARMACEUTICAL

  
    C-U
    
      
        
          0001639681
          XXXXXXXX
        
        020-26711
      
      LIVE
      
        false
        false
        false
      
    
  
  
    
      Adjustment to the initial Form C-U filing of 05/03/2021. At the close of the offering, the issuer closed on $228,459.00 and 56,806 number of securities.
      
        BIOCURITY PHARMACEUTICALS INC.
        
          Corporation
          DE
          10-16-2016
        
        
          110 FRONT STREET, SUITE 300
          SUITE 300
          JUPITER
          FL
          33477
        
        http://www.biocurity.com/
      
      N
      StartEngine Capital, LLC
      0001665160
      007-00007
    
    
      7.0 percent
      Two percent (2%) of securities of the total amount of investments raised in the offering, along the same terms as investors.
      Other
      Series 2 CF Convertible Preferred Stock
      2352
      4.25000
      N/A
      9996.00
      Y
      Other
      At issuer's discretion, with priority given to StartEngine Owners
      599998.00
      04-30-2021
    
    
      1.00
      222611.00
      342484.00
      62215.00
      167281.00
      0.00
      0.00
      1524330.00
      780203.00
      0.00
      0.00
      0.00
      0.00
      0.00
      0.00
      0.00
      0.00
      -2191060.00
      -1570893.00
      AL
      AK
      AZ
      AR
      CA
      CO
      CT
      DE
      DC
      FL
      GA
      HI
      ID
      IL
      IN
      IA
      KS
      KY
      LA
      ME
      MD
      MA
      MI
      MN
      MS
      MO
      MT
      NE
      NV
      NH
      NJ
      NM
      NY
      NC
      ND
      OH
      OK
      OR
      PA
      PR
      RI
      SC
      SD
      TN
      TX
      UT
      VT
      VA
      WA
      WV
      WI
      WY
    
    
      
        BIOCURITY PHARMACEUTICALS INC.
        MerchantCass Advisors, LLC Nancy Cass
        Principal Executive Officer
      
      
        
          MerchantCass Advisors, LLC Nancy Cass
          Principal Executive Officer
          06-21-2021
        
        
          Dr. Cheryl Baker, PhD
          Scientific Founder and Director, Principal Financial Officer and Principal Accounting Officer
          06-21-2021
        
      
    
  

You May Also Be Interested In

• CodeSignal Named One of the World's Top EdTech Companies in 2024
• Comprehensive Network Surveillance and Optimization
• Softgel Capsule Market to Surpass USD 14.06 Billion by 2031 Driven by Rising Demand for Nutraceuticals and Technological Advancements